ClinicalTrials.gg
Status unknownNCT03487653Updated Jul 6, 2018

Detection of the Most Common Microorganism of Infective Endocarditis in Assiut University Hospital

An observational study in Infective Endocarditis, sponsored by Safaa Samir. Status unknown. Per ClinicalTrials.gov, last updated 2018-07-06.

Sponsored by Safaa Samir · Observational

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

Indocarditis is an endogenous infection acquired when organisms entering the blood

stream establish on the heart valves, therefore, any bacteremia can potentially result in endocarditis.

Infective endocarditis is an uncommon disease that often presents as pyrexia of unknown origin.

The mortality rate in endocarditis was very high before the antibiotic era, even now a day, the

mortality rate is around 20%(1).A variety of microorganisms can cause IE; staphylococci and streptococci account for the majority of cases. Staphylococcal IE is a common cause of healthcare-associated IE ; streptococcal IE is a common cause of community-acquired IE. Common bacterial pathogens include Staphylococcus aureus , Viridans group streptococci , Enterococcus, Coagulase-negative staphylococci , Streptococcus bovis , other streptococci , gram-negative bacteria, HACEK organisms in this category include a number of fastidious gram-negative bacilli: Haemophilus aphrophilus(subsequently called Aggregatibacter aphrophilus and Aggregatibacter paraphrophilus); Actinobacillus actinomycetemcomitans (subsequently called Aggregatibacter actinomycetemcomitans); Cardiobacterium hominis; Eikenella corrodens; and Kingella kingae , and fungi (1,2). A variable proportion of IE remain blood culture- negative (1-4). Most clinically significant bacteremias are detected within 48 hours; common and fastidious pathogens (such as members of the HACEK group) may be detected within five days of incubation with modern automated blood culture detection systems. The optimal volume of blood for each blood culture in adults is 20 ml.

Zoonotic agents, such as Coxiella burnetii, Brucella spp., and Bartonella spp. were frequently detected in North Africa and identified as causes of infective endocarditis (IE) in Egypt (3,4).Blood culture is the most important investigation for diagnosing infective endocarditis

andto know the prevalence rate of different bacteria and their antibiotic sensitivity pattern.Positive blood culture is the cornerstone of microbiological diagnosis of IE; three sets of blood cultures detect 96 to 98 percent of bacteremia. At least three sets of blood cultures should be obtained from separate venipuncture sites prior to initiation of antibiotic therapy. Patients with IE typically have continuous bacteremia; therefore, blood cultures may be collected at any time and need not necessarily be obtained at the time of fever or chills.

MATERIAL and METHOD A total of 150 blood cultures were received from 50 clinically diagnosed cases of bacterial endocarditis .

Blood sample was collected under all aseptic precautions.

02

Conditions studied

  • Infective Endocarditis

Browse trials for

03

In context

Endocarditis

173 studies on the registry are indexed under Endocarditis; 57 are open to participants now.

This study's planned enrollment of 50 is below the median of 225 across 82 observational studies indexed under Endocarditis.

Browse Endocarditis studies →

Lead sponsor

This is the only study on the registry with Safaa Samir as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Detection of the most common organism of infective endocarditis

Eligibility criteria

Inclusion Criteria:patients that are clinically diagnosed as infective endocarditis before starting antibiotics

Exclusion Criteria:patients that receive antibiotics before taking the blood sample

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • Biologicalmicrobiology:Blood culture and sensitvity test .Serology

    Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done

06

What researchers measure

Primary outcomes

  1. Detection of the most common micro organism of infective endocarditis

    Detection of the most common microorganism of infective endocarditis

    Time frame: 2years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2018; primary completion for Mar 2019, 3 months later.

Of 36 observational studies under Endocarditis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 36. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2018
First posted
Apr 4, 2018
StartEst.
Dec 1, 2018
Primary completionEst.
Mar 1, 2019
CompletionEst.
Dec 30, 2019
Last update
Jul 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03487653
Lead sponsor
Safaa Samir
Responsible party
Safaa Samir (Principle investigator, Assiut University) — Sponsor-investigator
First posted
Apr 4, 2018
Start date
Dec 1, 2018 (estimated)
Primary completion
Mar 1, 2019 (estimated)
Completion
Dec 30, 2019 (estimated)
Last update
Jul 6, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion